Intellia Therape SEC Filings

Intellia Therapeutics' President and CEO, who is also a director, reported stock option exercises and related share sales in company stock. On 12/11/2025, the reporting person exercised options to acquire 49,959 shares of common stock at an exercise price of $ 6.83 and sold 49,959, 32,832 and 5,355 shares in separate transactions with weighted average prices of $ 9.49, $ 9.47 and $ 9.59, respectively.

On 12/12/2025, additional options for 8,557 shares were exercised at $ 6.83. These option awards were granted under the company’s 2015 Stock Option and Incentive Plan and had vested in full as of 12/11/2025. The filing notes that the sales occurred automatically under a Rule 10b5‑1 trading plan adopted on 09/11/2025. Following these transactions, the reporting person beneficially owns 1,047,485 shares directly and 58,415 shares indirectly through the John M. Leonard 2015 Irrevocable Trust.

Intellia Therapeutics (NTLA) reported new clinical updates across two in vivo CRISPR programs. For hereditary angioedema, a pooled Phase 1/2 analysis of 32 patients receiving a one-time 50 mg dose of lonvoguran ziclumeran (lonvo-z) showed a mean 89% reduction in plasma kallikrein at month 24. 31 of 32 patients (97%) were attack-free and off long-term prophylaxis as of the August 29, 2025 cut-off, with a safety profile described as well tolerated up to three years of follow-up. The global Phase 3 HAELO trial completed enrollment in September 2025, with topline data expected by mid-2026.

For transthyretin amyloidosis with cardiomyopathy, the Phase 1 trial of nexiguran ziclumeran (nex-z) enrolled 36 patients and showed sustained serum TTR reduction; among nine patients at 36 months, the mean reduction was 87%. At 24 months, stability or improvement was seen in 70% (NT-proBNP), 85% (hs‑Troponin T), and 69% (6MWT), with 81% stable or improved NYHA class. A matched-cohort mortality analysis reported HR 0.27 (p=0.009). The FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE‑2 trials on October 29, 2025.

Intellia Therapeutics (NTLA) reported Q3 2025 results showing collaboration revenue of $13,782 and a net loss of $101,324. Operating expenses fell year over year as research and development declined to $94,747 from $123,380, while general and administrative was essentially flat at $30,512. Other income, net, was $10,153, driven primarily by interest income.

Liquidity remained sizable with cash and cash equivalents of $193,389 and marketable securities of $476,469 as of September 30, 2025. Year to date, the company raised $128,175 through at-the-market share sales and ended the quarter with 115,787,285 shares outstanding; 115,829,926 shares were outstanding as of October 31, 2025. Stockholders’ equity was $748,422.

Strategic updates included a January workforce reduction of about 27% with $6,500 in restructuring charges. The company amended and partially terminated facility leases, paying $34,000 in February and $30,000 in April 2025, with $14,000 due in January 2026, and recorded $40,500 of prepaid rent tied to a new Tech Square lease. Collaboration activity included a $1,800 milestone recognized under the Regeneron agreements, termination of the ReCode agreement in September 2025, and termination of the SparingVision collaboration in October 2025 with the return of 50% of its Series A2 shares.

Intellia Therapeutics (NTLA) filed an 8-K announcing its financial results and business updates for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 detailing the announcement.

The information provided under Item 2.02 is furnished, not deemed filed under Section 18 of the Exchange Act, and may be incorporated by reference only if a subsequent filing specifically references it.

Intellia Therapeutics (NTLA) reported an FDA clinical hold on the Investigational New Drug applications for its MAGNITUDE and MAGNITUDE‑2 Phase 3 trials of nexiguran ziclumeran (nex‑z). The company was verbally informed on October 29, 2025, and the FDA indicated it will issue a formal Clinical Hold Letter within 30 calendar days.

The hold follows a previously disclosed patient case with Grade 4 liver transaminases and increased total bilirubin in the MAGNITUDE trial. On October 27, 2025, Intellia had already paused dosing and screening in both Phase 3 studies under the trial’s protocol‑defined pausing criteria. Intellia stated it intends to work with the FDA to address the hold as expeditiously as possible.

Intellia Therapeutics temporarily paused dosing and screening in its Phase 3 MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) trials of nexiguran ziclumeran (nex-z) after a safety event met protocol-defined pausing criteria.

The action follows an October 24 report of Grade 4 liver transaminases and increased total bilirubin in a patient dosed on September 30 in MAGNITUDE. More than 650 patients with ATTR-CM are enrolled in MAGNITUDE and 47 patients with ATTR-PN are enrolled in MAGNITUDE-2; over 450 patients are estimated to have been dosed with nex-z. The company furnished a press release as Exhibit 99.1 and included standard forward-looking statements regarding the ability to resume and complete these studies.

Intellia Therapeutics (NTLA) reported an insider transaction by its EVP and Chief Scientific Officer. On October 1, 2025, the officer executed a mandatory sell-to-cover of 31 shares of common stock at $17.38 to satisfy tax withholding upon RSU vesting, which the filing notes was not a voluntary trade.

Following the transaction, the officer directly beneficially owned 105,184 shares of Intellia common stock.

Michael P. Dube, Vice President and Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA), reported a Form 4 disclosing a mandatory tax-withholding sale related to RSU vesting. On 10/01/2025 the reporting person had 1,871 shares sold (transaction code S(1)) at $17.38 per share to satisfy tax withholding obligations arising from RSU vesting. After the sale, the reporting person beneficially owned 55,266 shares. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025. The filing describes the sale as non-volitional and linked solely to tax withholding.

Intellia Therapeutics reported interim clinical data for its in vivo CRISPR gene editing therapy "nex-z" (NTLA-2001) in hereditary transthyretin (ATTR) amyloidosis with polyneuropathy. In an open-label Phase 1 study, a one-time dose at or above 0.3 mg/kg (n=33) produced a mean serum TTR reduction of 92% at 24 months, corresponding to a mean absolute TTR level of 17.3 µg/mL (95% CI 12.5–22.2). Among 12 patients followed to 36 months, mean reduction was 90% with a mean absolute level of 20 µg/mL (95% CI 11.2–28.8).

Clinical measures such as quality-of-life for diabetic neuropathy (QoL-DN) and neurofilament light chain (NfL) trended toward improvement, and 89% of patients showed improvement or stability in PND scores through 24 months versus baseline. The filing also reiterates standard development and collaboration risks, including regulatory and development uncertainties and reliance on partners.